Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes

Journal of Clinical Pharmacology

Volumn 36, Issue 3, 1996, Pages 274-279

  Abbott, Kevin ^a   Smith, Amy ^b   Bakris, George L ^b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCIUM ANTAGONIST; CREATININE; GLUCOSE; HEMOGLOBIN A1C; ISRADIPINE; NIFEDIPINE; PROTEIN; SODIUM;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SODIUM RESTRICTION;

EID: 0029968243     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04199.x     Document Type: Article

References (25)

1. Bakris G: Hypertension in diabetic patients. An overview of intervention studies to preserve renal function. Am J Hypertens 1993; 6:140S-147S.
2. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long term stabilizing effect of angiotensin converting enzyme inhibition on plasma creatinine and proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118:577-581.
3. Maki DD, Ma JZ, Louis TA, Kasiske BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155:1073-1080.
4. Gaber L, Walton C, Brown S, Bakris GL: Effect of antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int 1994; 46:161-169.
5. Hebert LA, Bain RP, Verme D, Cattran D, Whittier FC, Tolchin N, et al: Remission of nephrotic range proteinuria in type I diabetes. Kidney Int 1994; 46:1688-1693.
6. Bakris GL, Copley B, Vicknair N, Leurgans S: Long term follow-up of patients with type II diabetes randomized to ACE inhibitors, calcium antagonists or both (abstract). J Am Soc Nephrol 1995; 6: 446.
7. Mimran A, Insua A, Ribstein J, Monnier L, Bringer J, Mirouse J: Contrasting effects of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. J Hypertens 1988; 6: 919-923.
8. Stornello M, Valvo EV, Scapellato L: Hemodynamics, renal and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy. J Cardiovasc Pharmacol 1989; 14:851-855.
9. Capewell S, Collier A, Matthews DL, Hajducka C, Collier R, Clark BF, et al: A trial of the calcium antagonist felodipine in hypertensive type II diabetic patients. Diabet Med 1989; 6:809-812.
10. Ferder L, Daccordi HA, Martello M,: Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension 1992; 19(suppl 11):II-237-II-242.
11. Frishman WH: Calcium-channel entry blocker therapy for hypertensive patients with concomitant renal impairment: a focus on isradipine J Clin Pharmacol 1994; 34:1164-1172.
12. Myers BD: Pathophysiology of proteinuria in diabetic glomerular disease. J Hypertens 1990;8(suppl 1):S41-S46.
13. Hartmann A, Lund K, Hagel L, Holdaas H, Fanchald P, Reissaeler A, Berg K: Contrasting short term effects of nifedipine on glomerular and tubular functions in glomerulonephritic patients. J Am Soc Nephrol 1994; 5:1385-1390.
14. Bohler J, Becker A, Reetze-Bonorden P, Woitas R, Keller E, Schollmeyer P: Effects of antihypertensive drugs on glomerular hyperfiltration and renal hemodynamics: a comparison of captopril with nifedipine, metoprolol and celiprolol. Eur J Clin Pharmacol 1993; 44(suppl 1):S57-S61.
15. Jerums G, Allen TJ, Tsalamandris C, Cooper ME: Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy. Kidney Int 1992; 41:904-911.
16. Gilbert RE, Jerums G, Allen T, Hammond J, Cooper ME on behalf of the Melbourne Diabetic Nephropathy Study Group: Effect of different antihypertensive agents on normotensive microalbuminuric patients with IDDM and NIDDM (abstract). J Am Soc Nephrol 1994; 5:377.
17. Bakris GL, Williams B: ACE inhibitors and calcium antagonists alone or combined: is there a difference on progression of diabetic renal disease? J Hypertens 1995; 13(suppl 2):S95-S101.
18. Zucchelli P, Zuccala A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, et al: Long term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42: 452-458.
19. Kamper AL, Strangaard S, Leyssac PP: Late outcome of a controlled trial of enalapril treatment on progressive chronic renal failure. Hard end points and influence of proteinuria. Nephrol Dial Transplant 1995; 10:1182-1188.
20. Abbott K, Sanders L, Bakris GL: Microalbuminuria in Type II diabetic patients: implications for prognosis and therapy. Arch Intern Med 1994; 154:146-153.
21. Heeg JE, de Jong PE, vanderHem GK, de Zeeuw D: Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36:272-279.
22. Bank N, Lahorra MA, Aynedjian HS, Wilkes BM: Sodium restriction corrects hyperfiltration of diabetes. Am J Physiol 1988; 254:F668-F676.
23. McEvoy GK (ed.): American Hospital Formulary Service Drug Information. Bethesda, MD: American Hospital Formulary Service, 1992.
24. Bakris GL: Blood pressure control and progression of diabetic nephropathy: are all antihypertensive drugs created equal? Kidney 1994; 3:61-62.
25. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD for the Collaborative Study Group: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-1462.